Tuberous Sclerosis Complex (TSC) is a multisystem autosomal dominant condition caused by inactivating pathogenic variants in either the TSC1 or the TSC2 gene, leading to hyperactivation of the mTOR pathway. Here, we present an update on the genetic and genomic aspects of TSC, with a focus on clinical and laboratory practice. We briefly summarize the structure of TSC1 and TSC2 as well as their protein products, and discuss current diagnostic testing, addressing mosaicism. We consider genotype-phenotype correlations as an example of precision medicine, and discuss genetic counseling in TSC, with the aim of providing geneticists and health care practitioners involved in the care of TSC individuals with useful tools for their practice.
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Tuberous Sclerosis Complex (TSC) is a multisystem autosomal dominant condition caused by inactivating pathogenic variants in either the TSC1 or the TSC2 gene, leading to hyperactivation of the mTOR pathway. Here, we present an update on the genetic and genomic aspects of TSC, with a focus on clinical and laboratory practice. We briefly summarize the structure of TSC1 and TSC2 as well as their protein products, and discuss current diagnostic testing, addressing mosaicism. We consider genotype-phenotype correlations as an example of precision medicine, and discuss genetic counseling in TSC, with the aim of providing geneticists and health care practitioners involved in the care of TSC individuals with useful tools for their practice. (OMIM #191092) gene. TSC has a prevalence of 1:20,000 and an incidence of 1:6,000-10,000 live births with no differences between ethnic groups or genders (O'Callaghan, Shiell, Osborne, & Martyn, 1998; Hong, Tu, Lin, & Lee, 2016) .
Pathogenic variants in TSC1 or TSC2 cause hyperactivation of the mechanistic Target of Rapamycin (mTOR) signaling and consequent deregulation of cell growth (Crino, 2013) resulting in the development of hamartomas (benign tumors) in various organ systems.
The genetic basis of TSC was included in the latest diagnostic criteria for TSC published in 2012, as comprehensive and reliable molecular testing of TSC1 and TSC2 has now become widely available worldwide (Northrup, Krueger, & International Tuberous Sclerosis Complex Consensus Group, 2013 ).
We will address genetic and genomic aspects of TSC, discuss updated genotype-phenotype correlations, and answer questions related to genetic counseling, providing the reader with useful tools for clinical and laboratory practice. Our intended audience for the review is clinical geneticists, genetic counselors, pediatricians, neurologists, and laboratory personnel.
| THE TSC1 AND TSCGENES
TSC is caused by heterozygous pathogenic variants in TSC1 or TSC2.
TSC1 was identified in 1997, despite the chromosomal locus having been mapped 10 years earlier by linkage analysis (Fryer et al., 1987; van Slegtenhorst et al., 1997) . The gene was identified using a comprehensive sequencing approach of 30 genes from a 900 Kb region within the mapping interval on chromosome 9q34. The TSC1 gene (OMIM #605284) spans a 53,286 bp region on chromosome 9q34.13 (chr9: 135, 766, 820, Nellist et al., 2009 ), although they are less frequently represented (~2%) than other small changes. TSC2 pathogenic variants include nonsense (~14.5%), small indels (~37.7%), missense (~25.7%), splice site variants (~16.6%), and genomic deletions (~5.4%) (Northrup, Koenig, Pearson, & Au, 2018) . All of them are inactivating mutations. Pathogenicity for some missense and inframe deletion mutations has been assessed through functional studies by Dr. Nellist's group .
Overall, pathogenic variants in TSC2 are found in 2/3 of TSC patients, and pathogenic variants in TSC1 are found in the remaining 1/3. A small percentage (5%-10%) of TSC patients have no mutation identified (NMI) or have a variant found with unknown significance (VUS) after undergoing ultra-deep next generation sequencing. Some patients previously classified as NMI were found to have low-level mosaic pathogenic variants or pathogenic variants in introns that affected splicing (Nellist et al., 2015; Tyburczy et al., 2015) . (Crino, 2013) .
Together with the protein product of the TBC1D7 gene (Santiago Lima et al., 2014; Sun et al., 2013; Zech, Kiontke, Mueller, Oeckinghaus, & Kümmel, 2016) , they form a heterotrimeric complex (the TSC protein complex) that serves as the main negative regulator of the mechanistic (or mammalian) target of rapamacyn (mTOR) signaling pathway that in turn is part of the larger PI3K/mTOR/AKT pathway (Dibble et al., 2012) . The mTOR pathway (Figure 2 ) acts through two protein complexes, mTORC1 and mTORC2. mTORC1 controls and promotes protein and lipid synthesis and cell growth and metabolism, and limits autophagy (Henske, Jóźwiak, Kingswood, Sampson, & Thiele, 2016) . Hamartin is important for stabilizing the TSC complex, while the GAP domain (GTPase Activating Protein) of tuberin acts on the active form of Ras Homologue Enriched in Brain with GTP (RHEB-GTP), thus converting RHEB-GTP to the inactive GDP-bound form, and blocking activation of mTOR.
Inactivating pathogenic variants in either TSC1 or TSC2 result in uncontrolled RHEB being bound to GTP (active form), leading to hyperactivation of the mTOR pathway and constitutive deregulation of protein synthesis, and cell growth (Henske et al., 2016) .
Of note, pathogenic variants in the third subunit of the TSC protein complex, TBC1D7, do not cause TSC, but instead a syndrome characterized by intellectual disability, macrocrania, patellar dislocation, and celiac disease (Alfaiz et al., 2014) . Bongaarts et al., 2017) . Recently, several studies demonstrated that biallelic loss (either second-hit point mutations or copy-neutral LOH) of TSC1/TSC2 is the primary driver event for angiomyolipoma development, and somatic mutations in other known cancer-associated genes are very rare (Giannikou et al., 2016) . Unlike human carcinomas, the genomic landscape of TSC hamartomas appears to be relatively homogenous showing a low somatic mutational burden relative to carcinomas (Martin et al., 2017) . Dr. Kwiatkowski's group identified second-hit TSC2 somatic mutations in some facial angiofibromas cells that were distinct from the germline TSC2 mutation (Tyburczy et al., 2014) . Interestingly half of the second-hit mutations found in facial angiofibromas were the classic changes resulting from UV-induced DNA damage and repair (CC>TT), unlike changes seen among germline mutations. Until a few years ago, molecular testing for TSC consisted of detection of point mutations in the coding regions and intron/exon boundaries of TSC1 and TSC2 through Sanger sequencing, and deletions/duplications analysis in both genes. Going forward we will refer to these modalities as conventional genetic testing. The diagnostic yield of these methods together was 75%-90%. With the advent of Next Generation Sequencing (NGS), targeted TSC1/ TSC2 panels have been able to identify pathogenic variants in a higher number of patients including some cases with mosaicism and intronic variants affecting splicing (Nellist et al., 2015; Tyburczy et al., 2015) . Other individuals, mainly adults with mild phenotypes and newborns, have been diagnosed through whole exome sequencing (WES) or other multigene panels. When TSC is suspected, we recommend that the gold standard genetic test in clinical practice should be a TSC1/TSC2 NGS panel, reflexed to del/dup analysis of the two genes in cases where the sequencing yields negative results. Multigene NGS panels (i.e., mTOR pathway panel, epilepsy panel, cerebral malformations panel, ID panel) and WES should be requested only when there is a differential including additional diagnoses beyond TSC. We will address more technical details of molecular testing in the following section.
| CURRENT MOLECULAR TESTING
When a novel variant in TSC1 or TSC2 is identified, the laboratory should follow the genetic criteria (Northrup and Krueger, 2013 ) and the American College of Medical Genetics and Genomics guidelines (Richards et al., 2015) to determine if the variant is studies may provide support in this process (Dunlop et al., 2011; Hoogeveen-Westerveld et al., 2011 .
| MOSAICISM AND NO MUTATION IDENTIFIED
TSC individuals who meet the diagnostic criteria but in whom a pathogenic variant could not be detected are usually referred to as no mutation identified (NMI). Conventional genetic testing carried a relatively high rate of NMI of 10%-25%. Newer techniques employing NGS significantly reduced the rate, by uncovering that some individuals previ- later, the pathogenic variant will be present only in certain tissues and only certain manifestations may be present in the patients. The frequency of somatic mosaicism for large deletions and duplications of TSC1 and TSC2 in affected individuals has been reported as about 5% (Northrup et al., 2018) . The actual rate of somatic mosaicism for single nucleotide variants has not been determined.
Two independent groups in the United States and Europe have demonstrated that over half of NMI individuals have mosaic or intronic variants in either TSC1 or TSC2 (Nellist et al., 2015; Qin et al., 2010; Tyburczy et al., 2015) . Tyburczy et al. (2015) found changes in 85% of NMI patients. It should be noted, however, that over a third of the identified changes were heterozygous variants that: had previously been missed by other testing; were TSC1 large deletions; or were variants of unknown significance recently demonstrated to cause loss of function (LOF). The authors showed that mosaicism can be found at very low levels-such as <1%-using deep sequencing, namely NGS panels with a median read depth of 500-5,000× for exonic regions. However, these variants were also detected in non-TSC control samples at an even lower level. Mosaic variants <1% would result from a mutational event involving one cell when the embryo is at A more recent collaborative study provided a comprehensive analysis of the genomic landscape of TSC, and identified TSC1 or TSC2 pathogenic variants in 97% of the samples analyzed from different hamartomas derived from TSC patients (Martin et al., 2017 ).
An important point to consider in clinical practice is also the tissue that will be analyzed. Historically, germline TSC1 and TSC2 pathogenic
The TSC-mTOR functional pathway. TSC1 protein (TSC1 hamartin), TSC2 protein (TSC2 tuberin) and TBC1D7 protein (TBCD7) form a functional complex and convert active RHEB-GTP to inactive RHEB-GDP via the GAP function of tuberin to downregulate mTORC1 activity. RHEB-GTP activates the mTORC1 complex to phosporylate 4E-BP1 to release eIF-4E for protein translation initiation. Activated mTORC1 also phosphorylates autophagy complex proteins (ULK1, Atg13 and FIP200) to inhibit autophagy. Active mTORC1 subsequently phosphorylates S6 K1 to activate S6 protein to promote protein synthesis. Activation of S6 K1 and eIF-4E both promote synthesis of proteins necessary for cell metabolism, growth and proliferation. Tuberin has been shown to be required for the mTORC2 complex that can activate AKT as a feedback mechanism of protein synthesis regulation and cell survival. In addition, activated mTORC1 can also promote adipogenesis via activating SREBP and mitochondria proliferation via activating pCG1α. Other consequence of activating mTORC1 also includes activating nucleotide synthesis. Together, mTORC1 activation facilitates cell growth and proliferation via RHEB-GTP that can be down-regulated by an activated tuberin/ hamartin/TBCD7 complex. Tuberin/hamartin/TBCD7 can be activated by phosphorylation by kinases responding to (a) high AMP/ATP ratio is high during energy stress (AMPK), (b) DNA damage (AMPK), (c) low nutrient conditions (GSK3), and (d) 
| GENOTYPE-PHENOTYPE CORRELATIONS
As addressed in the previous sections, among patients with a pathogenic variant identified, 2/3 are found in TSC2, and 1/3 is found in TSC1. Individuals with a variant in TSC2 are more often simplex cases with a TSC2/TSC1 ratio of 3.4:1, while familial cases are equally distributed between patients with TSC1 and TSC2 pathogenic variants (Northrup et al., 2018) . Penetrance is complete, meaning that a person with a pathogenic variant in TSC1/TSC2 will exhibit signs and symptoms of TSC, although the phenotype can be variable and subtle in some cases.
The Individuals with this chromosomal microdeletion on 16p13.3 have TSC and early onset polycystic kidney disease (Brook-Carter et al., 1994) . PKD1 (OMIM #173900) overlaps with TSC2 at the 3 0 end of the genes, and is transcribed in the opposite direction. While changes in PKD1 cause autosomal dominant polycystic kidney with variable age at onset, the renal phenotype associated with the TSC2-PKD1
contiguous gene deletion is characterized by the detection of large kidneys with multiple cysts in utero or in infancy. This is in contrast also with the later appearance of renal cysts seen in TSC caused by changes in TSC1/TSC2 only. Newborns and infants with features of both TSC and polycystic kidney disease should be tested for the contiguous gene deletion syndrome.
Over the years, improved molecular techniques (Next Generation Sequencing) and more detailed clinical assessment (deep phenotyping or next generation phenotyping, or that is, imaging being more readily available and employed to assess TSC patients) have allowed better delineation of some genotype-phenotype correlations and refinement of the general rule mentioned above. We report correlations for only the TSC1/TSC2 variants that have been demonstrated to be pathogenic based on either the ACMG guidelines (Richards et al., 2015) or on functional studies.
For instance, van Eeghen, Nellist, van Eeghen, and Thiele (2013) found that Although this study has not been replicated and its main limitation was that it did not include many of the~30 missense pathogenic variants reported in exons 23-33 of TSC2 thus far, previous correlations for specific pathogenic variants in the same exons had been reported. The c.2714G>A (p.Arg905Gln) variant in exon 23 of TSC2 is associated with a mild phenotype (Jansen et al., 2006) . Individuals from six families with the variant exhibited fewer cortical tubers, milder skin, and renal involvement than seen in other patients, and seizures that responded well to antiepileptic treatment. Interestingly, different missense mutations in the same codon were associated with a more severe phenotype:
c.2713C>T (p.Arg905Trp) and c.2713C>G (p.Arg905Gly). The latter two variants were shown to have a different impact on protein function in functional studies (Jansen et al., 2006) . Similarly, the c.3598C>T (p.
Arg1200Trp) change in exon 29 of TSC2 was seen in individuals from seven families with mild skin lesions, remitting epilepsy, and a lack of severe ID or major organ involvement (Wentink et al., 2012) . The patho- Recently, Farach et al. (2017) found that the c.1864C>T (p.
Arg622Trp) variant in exon 17 of TSC2 is associated with a mild phenotype, with patients either having manifestations with little clinical relevance or not meeting criteria for a clinical diagnosis of TSC despite meeting the genetic criteria.
An important finding for the laboratory is that variants in exons 25 and 31 of TSC2 are very unlikely to cause classical TSC (Ekong et al., 2016) . Exons 25 and 31 are subject to alternative splicing, and the authors showed that they are less conserved among species than the other exons in TSC2, are present in low abundance in adult tissues, and are not necessary for TSC complex function in regulating mTOR activity in these tissues. However, transcripts with exons 25 and 31 are more abundant in fetal tissues and their biological role in fetal tissues has not been fully investigated.
To the best of our knowledge, no genotype-phenotype correlations regarding specific pathogenic variants in TSC1 have been reported.
With regard to NMI patients, the delineation of their phenotype is likely to change with the increased number of pathogenic variants identified by improved sequencing technologies and functional assays for missense and intronic variants, leading to a more precise characterization of the phenotype of those who remain NMI. For now, a considerable number of NMI individuals have a distinctive phenotype, which can be summarized as milder than those with TSC2 pathogenic variants and similar but more severe with respect to renal findings than those with a TSC1 pathogenic variant (Camposano, Greenberg, Kwiatkowski, & Thiele, 2009; Peron et al., 2018) . The only caveat to this general statement is that some NMI individuals with a severe clinical presentation have been reported.
Finally, the increasing role of mTOR inhibitors for treatment of clinical manifestations of TSC prompted a study by Kwiatkowski et al. (2015) , showing that response of SEGAs and angiomyolipomas to mTOR inhibitors is independent of the mutation type and location, and is seen also in NMI individuals. and could possibly lead to a revision of the surveillance and management guidelines, which will likely need to be tailored accordingly in the future (Peron et al., 2018) .
| GENETIC COUNSELING
TSC is inherited in an autosomal dominant manner. As discussed earlier in this article, 2/3 of affected individuals have de novo pathogenic variants in TSC1 or TSC2, and 1/3 inherit the condition from an affected parent, who may have gone undiagnosed if he or she exhibits mild clinical manifestations. Therefore, it is of paramount importance to obtain either genetic testing (e.g., segregation analysis of the pathogenic variant) or full clinical evaluation of the parents, to determine whether the variant was inherited or arose de novo. If the pathogenic variant is not identified in either parent, the likelihood that they are affected is low, though never zero, due to the possibility of somatic mosaicism-which is unlikely to be detected on DNA from blood-or confined gonadal mosaicism (Roberts et al., 2004; Rose et al., 1999 ).
In addition to informing patients and families about natural history, clinical variability, molecular testing and their diagnostic yield and significance, the role of genetic counselors and geneticists is to explain the genetic risk and provide information to help make informed medical decisions. We will briefly discuss here different scenarios regarding risk assessment in TSC.
| Risk to family members
1. Parents of a proband: If a patient has a de novo pathogenic variant, the recurrence risk for his/her parents to have another child with TSC is low (1%-2%), but significantly greater than that of the general population, due to the possibility of confined gonadal mosaicism in the parents, as discussed above. In fact, families with two or more affected children and unaffected parents have been reported, and germline mosaicism in TSC has been estimated to be up to 2% (Rose et al., 1999) .
2a. Proband with a heterozygous pathogenic variant: An affected
individual has a 50% risk of passing the pathogenic variant to his/her children, regardless of the gender. Individuals who inherit the pathogenic variant will be affected. However, it is currently impossible to predict the phenotype based solely on the mutation, and the wide intrafamilial clinical variability of TSC should be explained.
2b. Proband with a mosaic pathogenic variant: Calculating the reproductive risk of mosaic patients is impossible. Therefore, a recurrence risk of up to 50% should be provided, and prenatal or preimplantation testing can be offered, as discussed in the next paragraph.
3. Other family members: The risk to other family members depends on the status of the proband's parents: if a parent is affected or has the familial pathogenic variant, his or her family members may be at risk. Appropriate genetic counseling to determine their risk and the indication to perform molecular testing should be offered
| Family planning
As discussed in the GeneReview dedicated to TSC, the best time to discuss reproductive options is before pregnancy (Northrup et al., 2018 (Hayward & Chitty, 2018) . To the best of our knowledge, however, this is currently offered only if the father is affected.
Adoption is another option that should be discussed. 
| CONCLUSIONS
TSC is caused by pathogenic variants in either TSC1 or TSC2, leading to hyperactivation of the mTOR pathway and occurrence of the clinical manifestations of the disease. In this review, we outlined genetic and genomic aspects of TSC, with attention to the emerging number of patients with mosaic variants. We summarized available genotypephenotype correlations as an example of precision medicine, noting that their use in clinical practice should be addressed with caution.
We provided scenarios for genetic counseling.
Although dramatic improvements in understanding the genetic aspects of TSC have been achieved since the identification of TSC1 
